Retroviral Vector—Mediated Cytokine-Gene Transfer into Tumor Cells

References

• Forni G, Giovarelli M. Strategies for cell-mediated immuno-therapy of cancer: Killing or help. Immunol Today 1986; 7: 202–203
   PubMedGoogle Scholar
• Erard F, Corthesy P, Nabholz M. Interleukin-2 is both necessary and sufficient for the growth and differentiation of lectin-stimulated cytolytic T lymphocyte precursors. J lmmunol 1985; 134: 1644–1649
   PubMed Web of Science ®Google Scholar
• Trinchieri G. Biology of natural killer cells. Adv Immunol 1989; 47: 187–232
   PubMed Web of Science ®Google Scholar
• Rosenberg S A, Lotze M T. Cancer immunotherapy using interleukin-2 and interleuken-2-activated lymphocytes. Annu Rev Immunol 1986; 4: 681–710
   PubMed Web of Science ®Google Scholar
• Rosenberg S A. Immunotherapy of cancer by the systemic administration of lymphoid cells plus interleukin-2. Biol Response Modif 1984; 3: 501–511
   PubMedGoogle Scholar
• Rosenberg S A, Lotze M T, Muul L M. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 in patients with met-astatic cancer. N Engl J Med 1985; 313: 1485–1492
   PubMed Web of Science ®Google Scholar
• Rosenberg S A, Mule J J, Spiess P I. Regression of established pulmonary metastases and subcutaneous tumors mediated by the systemic administration of high dose recombinant inter-leukin 2. J Exp Med 1985; 161: 1169
   PubMed Web of Science ®Google Scholar
• Rosenberg S A. Immunotherapy of patients with advanced cancer using interleukin-2 alone or in combination with lymphokine-activated killer cells. In: Important Advances in Oncology. Lippincott, Philadelphia 1988; 217
   Google Scholar
• Rosenberg S A, Lotze M T, Yang J C. Combination therapy with interleukin-2 and alpha interferon for treatment of patients with advanced cancer. J Clin Oncol 1989; 7: 1863–1874
   PubMed Web of Science ®Google Scholar
• Rosenberg S A, Spiess P, Lafreniere R. A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science 1986; 223: 1218–1321
   Google Scholar
• Rosenberg S A. Immunotherapy and gene therapy of cancer. Cancer Res 1991; 51: 5074–5079
   PubMed Web of Science ®Google Scholar
• Rosenberg S A. Kamofsky memorial lecture: The immunotherapy and gene therapy of cancer. J Clin Oncol 1992; 10: 180–199
   PubMed Web of Science ®Google Scholar
• Thatcher N, Dazzu H, Johson R J. Recombinant interleukin-2 given intrasplenically and intravenously for advanced malignant melanoma. A phase I and II study. Br J Cancer 1989; 60: 770–774
   PubMed Web of Science ®Google Scholar
• Konrad M W, Hemstreet G, Hersh E M. Pharmacokinetics of recombinant interleukin 2 in humans. Cancer Res 1990; 50: 2009–2017
   PubMed Web of Science ®Google Scholar
• Rosenberg S A, Lotze M T, Yang J C. Experience with the use of high-dose interleukin-2 in the treatment of 652 patients with cancer. Ann Surg 1989; 210: 474–485
   PubMed Web of Science ®Google Scholar
• Lotze M T, Frana L W, Sharrow S O. In vivo administration of purified human interleukin-2. I. Half life and immunologic effects of the Jurkat cell line drived IL-2. J Immunol 1985; 134: 157–166
   PubMed Web of Science ®Google Scholar
• Lotze M T, Matory Y L, Ettinghausen S E. In vivo administration of purified human interleukin-2. II. Half life and immunologic effects and expansion of peripheral lymphoid cells in vivo with recombinant IL-2. J lmmunol 1985; 135: 2865–2875
   PubMed Web of Science ®Google Scholar
• Rosenberg S A, Spiess P, Lafreniere R. A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science 1986; 233: 1318
   PubMed Web of Science ®Google Scholar
• Rosenberg S A, Aebersold P, Cometta K. Gene transfer into humans: Immunotherapy of patients with advanced melanoma using tumor-infiltrating lymphocytes modified by retrieval gene transduction. N Engl J Med 1990; 8: 570–578
   Google Scholar
• Kasid A, Morecki S, Aebersold P. Human gene transfer: Characterization of human tumor-infiltrating lymphocytes as vehicles for retroviral-mediated gene transfer in man. Proc Natl Acad Sci USA 1990; 871: 473–477
   Google Scholar
• Morecki S, Karson E, Cornetta K. Retrovirus-mediate gene transfer into CD4 + and CD8 + human T cells subsets derived from tumor-infiltrating lymphocytes and peripheral blood mono-nuclear cells. Cancer Immunol Immunother 1991; 32: 342–352
   PubMed Web of Science ®Google Scholar
• Gansbacher B, Bannerji R, Daniels B. Retroviral vector-mediated gamma interferon gene transfer into tumor cells generates potent and long lasting antitumor immunity. Cancer Res 1990; 50: 7820–7825
   PubMed Web of Science ®Google Scholar
• Teppcr RI., Pattengal P K, Leder P. Murine interleukin-4 displays potent anti-tumor activity in vivo. Cell 1989; 57: 503–512
   PubMed Web of Science ®Google Scholar
• Watanabe Y, Kuribayashi K, Miyatake S. Exogenous expression of mouse interferon-gamma cDNA in mouse neuro-blastoma C1300 cells results in reduced tumorigenicity by augmented anti-tumor immunity. Proc Natl Acad Sci USA 1989; 86: 9456–9460
   PubMed Web of Science ®Google Scholar
• Gansbacher B, Zier K, Daniels B. IL-2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity. J Exp Med 1990; 172: 1217–1224
   PubMed Web of Science ®Google Scholar
• Blankenstein T, Li W, Muller Q. W. Retroviral interleukin 4 gene transfer into an interleukin 4-dependent cell line results in autocrine growth but not in tumorigenicity. Eur J Immunol 1990; 20: 935–938
   PubMed Web of Science ®Google Scholar
• Bubenik J, Voitenok N, Kieler N. J, Prassolov V S, Chumakov P M, Bubenikova D, Simova J, Jandlova T. Local administration of cells containing an inserted IL-2 gene and producing IL-2 inhibits growth of human tumors in nu/nu mice. lmmunol Lett 1988; 19: 279–282
   PubMed Web of Science ®Google Scholar
• Blankenstein T, Qin Z H, Uberia K. Tumor suppression after tumor cell-targeted tumor necrosis factor alpha gene transfer. J Exp Med 1991; 173: 1047–1052
   PubMed Web of Science ®Google Scholar
• Asher A L, Mule J, Kasid J. A. Murine tumor cells transduced with the gene for tumor necrosis factor-alpha. J Immunol 1991; 146: 3227–3234
   PubMed Web of Science ®Google Scholar
• Golumbek P T, Lazenby A J, Levitzky H I. Treatment of established renal cancer engineered to secrete interleukin-4. Science 1991; 254: 713
   PubMed Web of Science ®Google Scholar
• Scala G, Quinto J., Ruocco M R. Expression of an exogenous interleukin 6 gene in human Epstein Ban virus B cells confers growth advantage and in vivo tumorigenicity. J Exp Med 1990; 172: 61–68
   PubMed Web of Science ®Google Scholar
• Fearon E R, Pardoll D M, Itaya T. Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response. Cell 1990; 60: 397–403
   PubMed Web of Science ®Google Scholar
• Gilboa E. Retrovirus vectors and their use in molecular biology. Bioassay 1986; 5: 252
   PubMed Web of Science ®Google Scholar
• Miller A D. Retrovirus packaging cells. Human Gene Ther 1990; 1: 5
   PubMed Web of Science ®Google Scholar
• Markowitz D, Goff S, Bank A. A safe packaging line for gene transfer: Separating viral genes on two different plasmids. J Virol 1988; 62: 1120–1124
   PubMed Web of Science ®Google Scholar
• Markowitz D, Goff S, Bank A. Construction and use of a safe and efficient amphotropic packaging cell line. Virology 1988; 167: 400–406
   PubMed Web of Science ®Google Scholar
• Armentano D, Yu S F, Kantoff P W. Effect of internal viral sequences on the utility of retroviral vectors. J Virol 1987; 61: 1647–1653
   PubMed Web of Science ®Google Scholar
• Oval J, Hershberg R, Gansbacher B. Expression of functional epidermal growth factor receptor in a human hematopoietic cell line. Cancer Res 1991; 51: 150–156
   PubMed Web of Science ®Google Scholar
• Gastl G., Finstad C, Golde L. D, Guarini A., Bosl G, Bander N., Gilboa E, Gansbacher B. Retroviral vector-mediated lymphokine gene transfer into human renal cancer cell lines. Cancer Res 1992; 52: 6229–6236
   PubMed Web of Science ®Google Scholar
• Foa R., Guarini A, Gansbacher B. 1L-2 treatment for cancer: From biology to gene therapy. Br J Cancer 1992; 66: 992–998
   PubMed Web of Science ®Google Scholar
• Gansbacher B., Zier K., Cronin K. Retroviral gene transfer induced constitutive expression of IL-2 or IFN-gamma by irradiated human melanoma cells. Blood 1993; X0: 2X17–2825
   Google Scholar
• Guarini B., Gansbacher A., Gilboa E. Lymphoma regreshim induced by gene transfer mediated localized IL-2 secretion. Blood 1928; 78, 10. Suppl 1
   Google Scholar
• Smyth M J, Ortaldo J R, Shinkai Y. Interleukin 2 induction of pore-forming protein gene expression in human peripheral blood CD8 T cells. J Exp Med 1990; 171: 1269
   PubMed Web of Science ®Google Scholar
• Nakagawa T, Hirano T, Nakagawa N. Effect of recombinant IL-2 and 1FN-gamma on proliferation and differentiation of human B cells. J lmmunol 1985; 134: 959–966
   PubMed Web of Science ®Google Scholar
• Mosmann T R, Yokota T, Kastelein R. Species-specificity of T cell stimulating activities of IL2 and BSF-I (IL4): Comparison of normal and recombinant, mouse and human IL2 and BSF-I (1L4). J Immunol 1987; 138: 1813–1816
   PubMed Web of Science ®Google Scholar
• Mosmann TR., Coffman R L. Two types of moule helper T-cell clone. lmmunol Today 1987; 8: 223–227
   PubMedGoogle Scholar
• Cher DJ., Mosmann T R. Two types of murine helper T cell clone. II. Delayed-type hypersensitivity is mediated by THI clones. J Imniunol 1987; 138: 3688–3694
   PubMed Web of Science ®Google Scholar
• Rees RC., Wiltrout R H. The biology and clinical applications of interleukin-2. lmmunol Today 1990; 11: 11–13
   Google Scholar
• Russell S J, Eccles S A, Flemming C L. Decreased tumorigenicity of a transplantable rat sarcoma following transfer and expression of an IL-2 cDNA. Int J Cancer 1991; 47: 244–251
   PubMed Web of Science ®Google Scholar
• Paul W E, Ohara J. B cell-stimulatory factor I interleukin 4. Annu Rev lmmunol 1987; 5: 429
   PubMed Web of Science ®Google Scholar
• Li W, Diamantstein Blankenstein T. T. Lack of tumorigeniclty of IL-4 autocrine growing cells seems related to the anti-tumor function of IL-4. Mol lmmunol 1990; 27: 1331
   PubMed Web of Science ®Google Scholar
• Nathan C, Yoshida R. Cytokines: Interferon-gamma. Intlammation: Basic Principles and Clinical Correlates. Raven Press, New York 1988; 229–251
   Google Scholar
• Chen L, Tourvieille B, Bums G F. Interferon: A cytotoxic T lymphocyte differentiation signal. Eur J lmmunol 1986; 16: 767–770
   PubMed Web of Science ®Google Scholar
• Maraskovsky E, Chen W, Shortman K. IL-2 and IFN-gamma are two necessary lymphokines in the development of cytolytic T cells. J Immunol 1989; 143: 1210–1214
   PubMed Web of Science ®Google Scholar
• Sone S, Utsugi T K, Ogura T. Differential effects of recombinant interferons alpha, beta and gamma on induction of human lymphokine (IL-2)-activated killer activity. J Natl Cancer lnst 1988; 80: 425–431
   PubMed Web of Science ®Google Scholar
• Balkwill F R. The regulatory role of interferons in the human immune response. Interferons: Their Impact in Biology and Medicine, J Taylor-Papadimitriou. Oxford Medical Publications, OxfordEngland 1985; 61–80
   Google Scholar
• Trinchieri G, Perussia B. Immune interferon: A pleiotropic lyniphokine with multiple effects. Immunol Today 1985; 6: 131–136
   PubMedGoogle Scholar
• Chen L K, Tourvieille B, Bums G F. Interferon-gamma: A cytotoxic T lymphocyte differentiation signal. Eur J Immunol 1986; 16: 767–770
   PubMed Web of Science ®Google Scholar
• Adam D O, Hamilton T A. Molecular transduction mechanism by which IFN-gamma and other signals regulate macrophage development. lmmunol Rev 1987; 97: 5–27
   PubMed Web of Science ®Google Scholar
• Nishihara K, Miyatake S, Sakata T. Augmentation of tumor targeting in a line of glioma-specific mouse cytotoxic T lymphocytes by retroviral expression of mouse gamma-interferon complementary DNA. Cancer Res 1992; 48: 4730–4735
   Google Scholar
• Esumi N, Hunt B, Ltaya T. Reduced tumorigenicity of murine tumor cells secreting IFN-gamma is due to nonspecific host responses and is unrelated to class I major histocompatibility complex expression. Cancer Res 1991; 51: 1185–1189
   PubMed Web of Science ®Google Scholar
• Barth RJ., Mule J J, Spiess P J. Interferon gamma and tumor necrosis factor alpha have arole in tumor regression mediated by murine CD8 + tumor infiltrating lymphocytes. J Exp Med 1991; 3: 647–658
   Google Scholar
• Schwartzentruber DJ., Topolian S N, Mancini M. Specific release of granulocyte-macrophage colony stimulating factor, tumor necrosis factor-alpha and interferon-gamma by human tumor infiltrating lymphocytes after autologous tumor stimulation. J Immunol 1991; 146: 3674–3681
   PubMed Web of Science ®Google Scholar
• Colombo M P, Ferrari G. Granulocyte colony-stimulating factor gene transfer suppresses tumorigenicity of a murine adenocar-cinoma in vivo. J Exp Med 1991; 1732: 389–897
   Google Scholar
• Alderson M R, Sassenfeld H M, Widmer M. Interleukin 7 enhances cytolytic T lymphocyte generation and induces lympho-kine activated killer cells from human peripheral blood. J Exp Med 1990; 172: 577
   PubMed Web of Science ®Google Scholar
• Hock H, Dorsch M, Diamantstein R. Interleukin-7 induces CD4 T cell dependent tumor rejection. J Exp Med 1991; 174: 1291–1298
   PubMed Web of Science ®Google Scholar
• Bottazzi B, Walter S, Govoni D. Monocyte chemotactic cytokine gene transfer modulates macrophage infiltration, growth, and susceptibility to IL-2 therapy of a murine melanoma. J lmmunol 1992; 148: 1280–1285
   PubMed Web of Science ®Google Scholar
• Karasuyama H, Tohyama N, Tada T. Autocrine growth and tumorigenicity of interleukin 2 dependent helper T cells transfected with the IL-2 gene. J Exp Med 1989; 169: 13–25
   PubMed Web of Science ®Google Scholar
• Yamada G, Kitamura H, Sonoda H, Harada H, Taki S, Mulligan R C, Osawa H, Diamantstein T. Retroviral expression of the human IL-2 gene in a rnurine T cell line results in cell growth autonomy and tumorigenicity. EMBO J 1987; 6: 2705
   PubMed Web of Science ®Google Scholar
• Browder T, Abrams J S, Wong P M, Nienhuis A. Mechanism of autocrine stimulation in hematopoietic cells producing IL-3 after retrovirus mediated gene transfer. Mol Cel Biol 1989; 9: 204–213
   PubMed Web of Science ®Google Scholar
• Wong P MC, Chung S W, Nienhuis A W. Retroviral transfer and expression of the IL-3 gene in hematopoietic cells. Genes Dev 1987; 1: 358–365
   PubMed Web of Science ®Google Scholar
• Blankenstein T, Li W Q, Uberla K. Retroviral interleukin 5 gene transfer into interleukin 5-dependent growing cell lines results in autocrine growth and tumorigenicity. Eur J lmmunol 1990; 20: 2699–2705
   PubMed Web of Science ®Google Scholar
• Smyth M J, Ortaldo J R, Bere W. IL-2 and IL-6 synergies to augment the pore-forming protein gene expression and cytotoxic potential of human peripheral blood T cells. J lmmunol 1990; 145: 1149
   Google Scholar
• Mule J J, McIntosh J K, Jablons D M. Antitumor activity of recombinant interleukin-6 in mice. J Exp Med 1990; 171: 629–636
   PubMed Web of Science ®Google Scholar
• Suematsu S, Matsuda T, Aozasa K. LgGl plasmacytosis in interleukin 6 transgenic mice. Proc Natl Acad Sci USA 1989; 86: 7547
   PubMed Web of Science ®Google Scholar
• Porgador A, Tzehoval E, Katz A, Vadai E, Revel M, Feldman M, Eisenbach L. Interleukin 6 gene transfection into Lewis lung carcinoma tumor cells suppresses the malignant phenotype and confers immunotherapeutic competence against parental meta-static cells. Cancer Res 1992; 52: 3679
   PubMed Web of Science ®Google Scholar
• Wolfel T, Klehmann E, Muller C. Lysis of human melanoma cells by autologous cytolytic T cells clones. Identification of human histocompatibility leukocyte antigen A2 as a restriction element for three different antigens. J Exp Med 1989; 170: 797–810
   PubMed Web of Science ®Google Scholar
• Knuth A, Danowski B, Oettgen H. T-cell mediated cytotoxicity against autologous malignant melanoma: Analysis with interleu-kin-2 dependent T-cell cultures. Proc Natl Acad Sci USA 1984; 81: 3511–3515
   PubMed Web of Science ®Google Scholar
• Mukherji B, MacAIister T J. Clonal analysis of cytotoxic T-cell response against human melanoma. J Exp Med 1983; 158: 240–245
   PubMed Web of Science ®Google Scholar
• Degiovanni G, Hainaut P, Lahaye T. Antigens recognized on a melanoma cell line by autologous cytolytic T lymphocytes are also expressed on freshly collected tumor cells. Eur J Immunol 1990; 20: 1865–1868
   PubMed Web of Science ®Google Scholar
• De Vries J E, Spits H. Cloned human cytotoxic T lymphocyte (CTL) lines reactive with autologous melanoma cells. J lmmunol 1984; 132: 510
   PubMedGoogle Scholar
• Kawakami Y, Zakut R, Topalian S L. Shared human melanoma antigens: Recognition by tumor-infiltrating lymphocytes in HLA-A2.I-transfected melanomas. J Immunol 1992; 148: 638–643
   PubMed Web of Science ®Google Scholar
• Hayashi Y, Hoon D S, Park M S. Induction of CD4+ cytotoxic T cells by sensitization with allogeneic melanomas bearing shared or cross-reactive HLA-A. Cell lmmunol 1992; 139: 411–425
   PubMed Web of Science ®Google Scholar
• Crowley N J, Vervaert C E, Seigler H F. Human xenograft-nude mouse model of adoptive immunotherapy with human melanoma-specific cytotoxic T-cells. Cancer Res 1992; 52: 394–399
   PubMed Web of Science ®Google Scholar
• Crowley N J, Slinghuff C L, Barrow T L. Generation of human autologous tumor specific cytotoxic T cells using HLA-A2 matched allogenic melanoma. Cancer Res 1990; 50: 492
   PubMed Web of Science ®Google Scholar
• Darrow T L, Sligluff C L, Seigler R. The role of HLA class I antigens in recognition of melanoma cells by tumor-specific cy-totoxis T lymphocytes: Evidence for shared antigens. J Immunol 1989; 142: 13329–3335
   Google Scholar
• Crowley N J, Darrow T L, Quinn-Allen M A. MHC-restricted recognition of autologous melanoma by tumor-specific cytotoxic T cells. Evidence for restriction by a dominant HLA-A allele. J lmmunol 1991; 146: 1692–1699
   PubMed Web of Science ®Google Scholar